The FDA is committed to the expanded access program which provides a pathway for patients to gain access to investigational drugs, biologics and medical devices for serious diseases and life-threatening conditions outside of clinical trials when no comparable or satisfactory approved alternative therapy options are available.
Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to strengthen FDA’s expanded access program
More from FDA News AlertsMore posts in FDA News Alerts »
- Coronavirus (COVID-19) Update: June 22, 2021
- Prairie Wolf Spirits, Inc. Issues Voluntary Nationwide Recall of Prairie Wolf Distillery Hand Sanitizer Packed in 16.9 Oz. and 20 Oz Bottles Because They Resemble Drink Containers
- Sanit Technologies Adds Label Clarification to Existing Voluntary Hand Sanitizer Recall
- FDA Approves First Oral Blood Thinning Medication for Children